Europe Molecular Diagnostics Market (2025-2032)
The Europe Molecular Diagnostics Market is projected to reach $13.25 billion by 2032, at a CAGR of 4% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 180
- Format
- PDF + Excel
- Report ID
- MRHC - 1041027
- Base year
- 2024
- 2032 · FORECAST
- $13.25B
- 2032
- $13.25B
- CAGR 2025–2032
- 4%
2024 baseline · 2025–2032 forecast at 4% CAGR · hover a bar for the value
Key highlights
In 2025, the Kits & Reagents Segment is Expected to Dominate the Europe Molecular Diagnostics Market
In 2025, the Laboratory Tests Segment is Expected to Dominate the Europe Molecular Diagnostics Market
In 2025, the Polymerase Chain Reaction (PCR) Segment is Expected to Dominate the Europe Molecular Diagnostics Market
In 2025, the Infectious Diseases Segment is Expected to Dominate the Europe Molecular Diagnostics Market
In 2025, the Hospitals & Clinics Segment is Expected to Dominate the Europe Molecular Diagnostics Market
Germany: Fastest-growing Country-level Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 13.25 billion |
| CAGR (2025–2032) | 4% |
| Format | PDF, Excel & Cloud Portal · 180 pages |
| Segments Covered | By Product & Service: Kits & Reagents, Instruments/Systems, Software & Services · By Test Type: Laboratory Tests, PoC Tests · By Technology: Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarrays, Mass Spectrometry, Sequencing · By Application: Infectious Diseases COVID-19, Hepatitis, HIV, Healthcare-associated Infections (HAIs), Chlamydia trachomatis/ Neisseria gonorrhoeae (CT/NG), Human papillomavirus (HPV), Tuberculosis, Influenza, Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Lymphoma, Leukemia · By End User: Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Other End Users · By Product: Reagents & Kits, Systems, Software |
| Countries Covered | Europe (RoE) |
| Key Companies | F. Hoffmann-La Roche Ltd, Hologic, Inc. (U.S.), QIAGEN N.V., Danaher Corporation (U.S.), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG, DiaSorin S.p.A, Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.) |
Report overview
Segments covered: product & service, test type, technology, application, end user, product. Regions: Europe.
Molecular diagnostics is a branch of medical and clinical laboratory science that involves the detection, identification, and measurement of specific genetic or molecular markers within a person's biological samples (e.g., blood, tissue, or other bodily fluids) to diagnose and monitor diseases, predict disease risk, and guide treatment decisions. It is a rapidly evolving field that has revolutionized the way various diseases are diagnosed and managed.
The growth of this market is driven by factors such as technological advancements in molecular diagnostics, the increasing use of PoC diagnostic tests, an increase in funding for the R&D of diagnostic products, the rising geriatric population, and the increasing prevalence of target diseases. However, unfavorable regulatory framework and cost of molecular diagnostic tests hamper the growth of this market to a notable extent. Additionally, developments in companion diagnostics are expected to offer significant growth opportunities for the players operating in the molecular diagnostics market. However, the dearth of skilled professionals is a challenging factor for the market.
Report infographic
Market dynamics
1 factors across 1 forceIncreasing Focus on Companion Diagnostics Creates an Opportunity for the Europe Molecular Diagnostics Market
Companion molecular diagnostics measure the levels of proteins, genes, or specific mutations to reveal specific and effective therapies for an individual’s condition. Companion diagnostics (CDx) is a form of personalized, stratified, and precision medicine that individualizes a patient’s treatment. CDx has expanded from oncology drugs to multiple therapeutic areas, and the number of combinations has grown significantly over the years. Also, personalized medicine for infectious diseases helps to orient the molecular management of infections. Molecular microbiology offers technologies that can detect and identify microorganisms rapidly. Determining the pharmacogenetic profiles of patients suffering from infectious diseases provides an additional assessment of the drug metabolizer phenotype and/or of the risk of potential adverse drug interactions. Personalized medicine is thus expected to help develop new therapies and new methods for disease detection.
European companies in this market are collaborating for the development and commercialization of CDx due to the growth potential of companion diagnostics. This will help the companies expand their product portfolios and strengthen their presence across regions. For instance, in April 2022, AstraZeneca plc (U.K.) and Amoy Diagnostics Co., Ltd. (China) signed a collaboration agreement for multiple companion diagnostics programs in China, Japan, and the European Union. Also, in September 2021, Merck KGaA (Germany) and Illumina, Inc. (U.S.) partnered to develop and commercialize companion diagnostic tests to identify genetic mutations in patients with HRD-positive tumors who are eligible for the PARP inhibitor targeted treatment.
Table of contents
13 chapters · 109 sections · 180 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Product & Service | Kits & Reagents | — |
| By Test Type | Laboratory Tests | — |
| By Technology | Polymerase Chain Reaction (PCR) | — |
| Other segments | Infectious Diseases | — |
| By Application | Hospitals & Clinics | — |
By Product & Service
- The Kits & Reagents Segment is Expected to Dominate the Europe Molecular Diagnostics Market
- Among the products & services included in the report, in 2025, the reagents & kits segment is expected to account for the largest share of the Europe molecular diagnostics market.
- Factors such as frequent and repetitive use of molecular diagnostic reagents & kits, availability of disease-specific kits for the early diagnosis of chronic and infectious diseases, and technological advancements in molecular diagnostics contribute to the segment’s largest share.
By Test Type
- The laboratory tests segment is expected to account for the largest share of the Europe molecular diagnostics market.
- Lab testing is the traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing.
- The laboratory technicians conduct the processing and testing and create a report for the clinician.
- The laboratory testing approach for molecular diagnostics has many advantages over other approaches.
- It has higher accuracy and reliability when compared to point-of-care testing, owing to which the adoption is more compared to PoC tests.
By Technology
- The polymerase chain reaction (PCR) segment is expected to account for the largest share of the Europe molecular diagnostics market.
- PCR allows rapid amplification of a specific segment of DNA.
- This technology is sensitive and thus helps in the diagnosis of diseases.
- It is effective for low-number targets and less expensive than other technologies, such as sequencing.
- Hence, the huge demand for PCR devices further contributes to the segment’s largest share.
Other segments
- The infectious diseases segment is expected to account for the largest share of the Europe molecular diagnostics market.
- The large market share of this segment is attributed to the rising incidence rates of infectious diseases and the increase in initiatives by government organizations toward their prevention by early diagnosis.
- In the U.K., the number of people diagnosed with sexually transmitted infections (STIs) reached 490.1 thousand in 2020 from 468.3 thousand in 2019.
- Thus, the growing burden of infectious diseases drives the demand for molecular diagnostics for infectious diseases.
By Application
- The hospitals & clinics segment is expected to account for the largest share of the Europe molecular diagnostics market.
- The high number of hospitals and clinics, the high prevalence of healthcare-associated infections (HAIs), and the increasing healthcare expenditure worldwide are driving the demand for molecular diagnostics products in the region.
- In Europe, several factors driving the growth in the genomic sector increase the adoption of molecular diagnostic products.
- For instance, the establishment of national programs or pan-European programs, such as the “1+ Million Genomes” initiative, which involves 23 countries across Europe and aims to improve the uptake of genomics by healthcare systems and in personalized healthcare.
Geographic analysis
Europe
Fastest growthThe market growth in Germany is attributed to the well-established healthcare system, the rise in healthcare spending, the rising incidence of chronic diseases, the aging population, efforts by the German Government to further improve the quality of healthcare, research for the development of new technologies, and a high number of patients suffering from hospital-acquired infections. According to GLOBOCAN, in 2020, 628,519 new cancer cases and 252,065 cancer deaths were reported in Germany. The cancer incidence rate is estimated to increase to 749,559 by 2040. Additionally, according to the Robert Koch Institute (Germany), an estimated 400,000–600,000 patients get hospital-acquired infections every year, of which 10,000–15,000 succumb to these infections. Thus, the high burden of chronic and infectious diseases is driving the demand for molecular diagnostics in Germany. Germany: Fastest-growing Country-level Market
Competitive landscape
- F. Hoffmann-La Roche Ltd · Switzerland
- Hologic, Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- Danaher Corporation (U.S.)
- Becton
- Dickinson and Company (BD) (U.S.)
- Siemens Healthineers AG · Germany
- DiaSorin S.p.A · Italy
- Abbott Laboratories (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Illumina, Inc. (U.S.)
Frequently asked questions
The Europe molecular diagnostics market study covers the market sizes & forecasts for various molecular diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the Europe molecular diagnostics market at the regional and country levels.
Cite this report
Meticulous Research. (2025). Europe Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2025 -2032) (Report No. MRHC - 1041027). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/europe-molecular-diagnostics-market-5710